CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.205
-0.065 (-1.99%)
As of 10:59AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.270
Open3.290
Bid3.230 x 800
Ask3.240 x 1100
Day's Range3.200 - 3.299
52 Week Range2.090 - 4.510
Volume53,043
Avg. Volume757,641
Market Cap328.82M
Beta2.48
PE Ratio (TTM)N/A
EPS (TTM)-0.211
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • ACCESSWIRE18 days ago

    Free Research Reports on Catalent and Three More Generic Drugs Stocks

    Today, WallStEquities.com takes a close look at the following Generic Drugs stocks: Catalent Inc. (NYSE: CTLT), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Diplomat Pharmacy Inc. (NYSE: DPLO). Generic pharmaceutical and medicine manufacturers develop prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals.

  • GlobeNewswirelast month

    Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of Daniel J. Brennan as Chief Commercial Officer. Mr. Brennan will be responsible for leading the Company’s marketing, sales and commercial operations as Catalyst prepares for a potential launch of Firdapse®. “We are pleased to welcome Dan to the Catalyst team, as he brings extensive experience in leading the commercial efforts at biopharmaceutical companies, particularly those focused on orphan, neurological diseases,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals.

  • GlobeNewswirelast month

    Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors

    Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive director and a member of the Audit Committee. Mr. Daly has supported the successful launch of 10 drugs during a 27-year career in the biotech and pharmaceutical industry.  With his appointment, the Opiant Board now consists of six members, four of whom are independent.

  • GlobeNewswire2 months ago

    Catalyst Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the Company will be presenting at the Jefferies 2018 Global Healthcare Conference, in New York. Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Wednesday, June 6 at 8:00 am ET.

  • GlobeNewswire2 months ago

    Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse® (Amifampridine Phosphate) for Lambert-Eaton Myasthenic Syndrome

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, announced today that its New Drug Application (NDA) for Firdapse® for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) has been accepted for a Priority Review by the U.S. Food and Drug Administration (FDA). Priority Review is granted by the FDA to drugs with the potential to address a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition.

  • ACCESSWIRE2 months ago

    Wired News – FDA Granted Approval to Eagle Pharma’s Bendamustine Hydrochloride RTD Solution in a 500ml Admixture

    LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on Eagle Pharma, Inc. (NASDAQ: EGRX) ("Eagle"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EGRX as the Company's latest news hit the wire. On May 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted final approval to the Company's ready-to-dilute (RTD) bendamustine hydrochloride (HCl) solution in a 500ml admixture for the treatment of patients with chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Active-Investors.com is currently working on the research report for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), which also belongs to the Healthcare sector as the Company Eagle Pharma.

  • Associated Press2 months ago

    Catalyst: 1Q Earnings Snapshot

    The Coral Gables, Florida-based company said it had a loss of 6 cents per share. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and Provides Corporate Update

    CORAL GABLES, Fla., May 09, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...

  • GlobeNewswire2 months ago

    Catalyst Pharmaceuticals to Hold First Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, May 10th, 2018

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release first quarter 2018 financial results after market close on Wednesday, May 9, 2018. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Thursday, May 10, 2018 to discuss the financial results and to provide a corporate update. A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com.

  • GlobeNewswire3 months ago

    Report: Developing Opportunities within Clean Energy Fuels, Catalyst Pharmaceuticals, Qorvo, Brunswick, DCT Industrial Trust, and Radius Health — Future Expectations, Projections Moving into 2018

    NEW YORK, April 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • GlobeNewswire3 months ago

    Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the first patient has been enrolled into its Phase 3 clinical trial (designated as MSK-002) to evaluate the efficacy and safety of Firdapse® (amifampridine phosphate) in patients with MuSK antibody positive Myasthenia Gravis (MuSK-MG).

  • Catalyst Pharmaceuticals files new drug application with FDA
    American City Business Journals4 months ago

    Catalyst Pharmaceuticals files new drug application with FDA

    The Coral Gables-based company is another step closer to bringing a new drug to market.

  • Associated Press4 months ago

    Catalyst reports 4Q loss

    On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 6 cents. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now
    Insider Monkey4 months ago

    Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now

    There are plenty of opportunities to invest in healthcare stocks, as there are thousands of companies, ranging from big and well-established pharmaceuticals that also pay substantial dividends, to small, emerging companies without any products on the market or revenue, but backed by their research into novelty therapies for various illnesses. When looking for healthcare stocks […]

  • When Will Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Breakeven?
    Simply Wall St.4 months ago

    When Will Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Breakeven?

    Catalyst Pharmaceuticals Inc’s (NASDAQ:CPRX): Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. With the latest financial year lossRead More...

  • What's in Store for Catalyst (CPRX) This Earnings Season?
    Zacks4 months ago

    What's in Store for Catalyst (CPRX) This Earnings Season?

    Investors focus will be on pipeline and regulatory updates during Catalyst's (CPRX) fourth-quarter earnings call.

  • 3 Drug Stocks That Soared This Week: Are They Buys?
    Motley Fool7 months ago

    3 Drug Stocks That Soared This Week: Are They Buys?

    Can Catalyst, Sucampo, and Peregrine keep the momentum going?